Tuesday, April 4, 2023

New Tool Predicts Response to Immunotherapy in Lung Cancer Patients

Blog

Posted on  by Douglas M. Sheeley, Sc.D., NIH Common Fund

Vesicle

New Tool Predicts Response to Immunotherapy in Lung Cancer Patients

With just a blood sample from a patient, a promising technology has the potential to accurately diagnose non-small cell lung cancer (NSCLC), the most-common form of the disease, more than 90 percent of the time. The same technology can even predict from the same blood sample whether a patient will...

Read More . . .


This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo

No comments:

Post a Comment

Private investors pour $50 billion into booming sector… investment opportunity

Unstoppable megatrend driven by hundreds of billions in government spending ...